Genzyme Seprafilm approval will allow broader use than panel recommendation, company exec says.
This article was originally published in The Gray Sheet
GENZYME SEPRAFILM APPROVAL WILL BE BROADER THAN PANEL RECOMMENDATION for the post-operative adhesion reduction product, the firm says. Speaking at a June 25 meeting of the Food and Drug Law Institute in Washington, D.C., Genzyme VP, Clinical, Medical and Regulatory Affairs Richard Moscicki, MD, said the company has "worked very successfully with the FDA reviewers -- despite working within the restraints of the advisory panel -- to develop a very broad, appropriate label for the use of Seprafilm" during open abdominal surgery.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.